Biomea Fusion Company Insiders
| BMEA Stock | USD 1.18 0.08 6.35% |
About 58% of Biomea Fusion's corporate insiders are selling. The analysis of the overall insider sentiment regarding Biomea Fusion suggests that many insiders are alarmed. Biomea Fusion employs about 42 people. The company is managed by 14 executives with a total tenure of roughly 98 years, averaging almost 7.0 years of service per executive, having 3.0 employees per reported executive.
Insider Sentiment 42
Mostly Selling
Selling | Buying |
Latest Trades
| 2024-09-30 | Michael J.M. Hitchcock | Acquired 10000 @ 10.06 | View | ||
| 2023-05-31 | A2a Pharmaceuticals, Inc. | Disposed 75000 @ 33.81 | View | ||
| 2023-05-12 | A2a Pharmaceuticals, Inc. | Disposed 25000 @ 33.84 | View | ||
| 2023-05-08 | A2a Pharmaceuticals, Inc. | Disposed 100000 @ 33.99 | View | ||
| 2023-04-20 | A2a Pharmaceuticals, Inc. | Disposed 200000 @ 29.12 | View | ||
| 2023-03-30 | Bihua Chen | Acquired 400000 @ 30 | View | ||
| 2022-11-14 | Michael J.M. Hitchcock | Acquired 5000 @ 7.93 | View |
Monitoring Biomea Fusion's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomea Fusion. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. Biomea Fusion Management Team Effectiveness
The company has return on total asset (ROA) of (0.7522) % which means that it has lost $0.7522 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.09) %, meaning that it created substantial loss on money invested by shareholders. Biomea Fusion's management efficiency ratios could be used to measure how well Biomea Fusion manages its routine affairs as well as how well it operates its assets and liabilities. As of January 29, 2026, Return On Tangible Assets is expected to decline to -1.64. The current year's Return On Capital Employed is expected to grow to -2.7. At present, Biomea Fusion's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 12.1 M, whereas Net Tangible Assets are forecasted to decline to about 80.4 M.As of January 29, 2026, Common Stock Shares Outstanding is expected to decline to about 26.5 M. The current year's Net Loss is expected to grow to about (70 M)Biomea Fusion holds a total of 70.7 Million outstanding shares. 30% of Biomea Fusion outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Shares in Circulation | First Issued 2020-03-31 | Previous Quarter 40.6 M | Current Value 40.6 M | Avarage Shares Outstanding 29.8 M | Quarterly Volatility 8.7 M |
Biomea Fusion Workforce Comparison
Biomea Fusion is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 1,020. Biomea Fusion holds roughly 42.0 in number of employees claiming about 4% of equities under Health Care industry.
Biomea Fusion Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Biomea Fusion insiders, such as employees or executives, is commonly permitted as long as it does not rely on Biomea Fusion's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Biomea Fusion insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Erdtmann Rainer M over three weeks ago Acquisition by Erdtmann Rainer M of 40000 shares of Biomea Fusion at 1.1013 subject to Rule 16b-3 | ||
Michael Hitchcock over a month ago Acquisition by Michael Hitchcock of 100000 shares of Biomea Fusion at 0.9918 subject to Rule 16b-3 | ||
Erdtmann Rainer M over two months ago Acquisition by Erdtmann Rainer M of 40000 shares of Biomea Fusion at 1.1013 subject to Rule 16b-3 | ||
Averill Julianne over two months ago Acquisition by Averill Julianne of 241177 shares of Biomea Fusion at 1.82 subject to Rule 16b-3 | ||
Erdtmann Rainer M over two months ago Acquisition by Erdtmann Rainer M of 14000 shares of Biomea Fusion at 10.767 subject to Rule 16b-3 | ||
Erdtmann Rainer M over three months ago Acquisition by Erdtmann Rainer M of 10000 shares of Biomea Fusion subject to Rule 16b-3 | ||
Chen Bihua over six months ago Insider Trading | ||
Averill Julianne over six months ago Insider Trading |
Biomea Fusion Notable Stakeholders
A Biomea Fusion stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Biomea Fusion often face trade-offs trying to please all of them. Biomea Fusion's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Biomea Fusion's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Franco CPA | CFO Officer | Profile | |
| Michael Hitchcock | Interim Director | Profile | |
| Juan MD | Chief Officer | Profile | |
| Caroline Dupont | Senior Contracts | Profile | |
| Stephan MD | Chief Officer | Profile | |
| Franco Valle | CFO Officer | Profile | |
| Ravi Upasani | Executive Property | Profile | |
| Ramses Erdtmann | President, CoFounder | Profile | |
| Thomas Butler | Chairman CoFounder | Profile | |
| Thorsten Kirschberg | Executive Chemistry | Profile | |
| Alex Cacovean | Vice Sciences | Profile | |
| Naomi Cretcher | Chief Officer | Profile | |
| Heow Tan | Chief Officer | Profile | |
| Caroline JD | Senior Contracts | Profile |
About Biomea Fusion Management Performance
The success or failure of an entity such as Biomea Fusion often depends on how effective the management is. Biomea Fusion management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Biomea management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Biomea management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.56) | (1.64) | |
| Return On Capital Employed | (2.84) | (2.70) | |
| Return On Assets | (1.56) | (1.64) | |
| Return On Equity | (3.09) | (2.93) |
Please note, the presentation of Biomea Fusion's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Biomea Fusion's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Biomea Fusion's management manipulating its earnings.
Biomea Fusion Workforce Analysis
Traditionally, organizations such as Biomea Fusion use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Biomea Fusion within its industry.Biomea Fusion Manpower Efficiency
Return on Biomea Fusion Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 3.3M | |
| Net Loss Per Executive | 9.9M | |
| Working Capital Per Employee | 1.1M | |
| Working Capital Per Executive | 3.3M |
Complementary Tools for Biomea Stock analysis
When running Biomea Fusion's price analysis, check to measure Biomea Fusion's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biomea Fusion is operating at the current time. Most of Biomea Fusion's value examination focuses on studying past and present price action to predict the probability of Biomea Fusion's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biomea Fusion's price. Additionally, you may evaluate how the addition of Biomea Fusion to your portfolios can decrease your overall portfolio volatility.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |